Table 3 Comparison of clinical data for pneumonia-related characteristics in HAP patients with XDRAB and non-XDRAB
|  | XDRAB (N = 21) N (%) | Non-XDRAB (N = 42) N (%) | P-value |
|---|---|---|---|
Age, ya | 77.5 ± 11.6 | 68.6 ± 18.4 | 0.023 |
Gender (M/F), n | 17/4 | 23/19 | 0.079 |
APACHE II scorea | 21.9 ± 6.8 | 18.0 ± 4.9 | 0.011 |
Related to hospitalizationa | 18 (85.7) | 30 (71.4) | 0.347 |
 Days of mechanical ventilation before XDRAB (days) | 10.5 ± 11.6 | 5.2 ± 5.8 | 0.059 |
 Hospital days before XDRAB (days) | 18.3 ± 11.3 | 12.6 ± 11.2 | 0.064 |
 Length of stay in the ICU (days) | 30.1 ± 20.0 | 21.4 ± 21.7 | 0.127 |
 Length of stay in the hospital (days) | 45.5 ± 28.8 | 38.5 ± 24.2 | 0.199 |
Associated disease, n (%) | |||
 COPD | 13 (61.9) | 9 (21.4) | 0.001 |
 Diabetes mellitus | 2 (9.5) | 10 (40.4) | 0.307 |
 Malignancy | 2 (9.5) | 9 (21.4) | 0.411 |
 Cardiac disease | 13 (61.9) | 6 (14.2) | 0.000 |
 Renal disease | 5 (23.8) | 2 (4.7) | 0.065 |
 Neurological disease | 8 (38.0) | 22 (52.3) | 0.422 |
Device, n (%) | |||
 Urinary catheter | 21 (100.0) | 36 (85.7) | 0.172 |
 Nasogastric tube | 21 (100.0) | 36 (85.7) | 0.172 |
 Mechanical ventilation | 16 (76.1) | 31 (73.8) | 1.000 |
Drug usage, n (%) | |||
 Glucocorticoids | 10 (47.6) | 18 (42.8) | 0.720 |
 PPIs | 14 (66.7) | 32 (76.1) | 0.422 |
Antimicrobial n (%) | |||
 Cephalosporin |  |  |  |
  Second generation | 3 (14.2) | 5 (11.9) | 1.000 |
  Third generation | 7 (33.3) | 18 (42.8) | 0.649 |
 β-lactamase inhibitor | 20 (95.2) | 31 (73.8) | 0.089 |
 Quinolone | 13 (61.9) | 19 (45.2) | 0.327 |
 Aminoglycoside | 2 (9.5) | 4 (9.5) | 1.000 |
 Carbapenem | 11 (52.3) | 11 (26.1) | 0.040 |
 Antimicrobial Combination therapy, n (%) | 11 (52.3) | 19 (45.2) | 0.593 |
Mortality, n (%) | 9 (42.8) | 15 (35.7) | 0.582 |